Skip to main navigation

About Us
Our Platform
Our Programs
Investors & Media
Careers
Contact

Press Releases

Press Releases

Year

Mar 26, 2020

SutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia

Foster City, CA, March 26, 2020 – SutroVax , a biopharmaceutical company dedicated to the delivery of superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the closing of a $110 million Series D preferred stock

Additional Formats

PDF Version

Jan 30, 2020

SutroVax Announces Executive Appointment

Jim Wassil appointed Chief Operating Officer Foster City, CA, March 26, 2020 – SutroVax , a biopharmaceutical company dedicated to the delivery of superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the closing

Additional Formats

PDF Version

Pagination

First page
Previous page
Page 1
Current page 2

Displaying 11 - 12 of 12

Print Page

RSS Feeds

Email Alerts

IR Contact

Copyright © 2020 Vaxcyte, Inc. All Rights Reserved

Client Header Links

About Us
Our Platform
Our Programs
Investors & Media
Careers
Contact